利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.026 秒)

    ECM-Complex Antibody Compositions and Methods of Use
    1.
    发明申请
    ECM-Complex Antibody Compositions and Methods of Use 审中-公开
    ECM复合物抗体组合物和使用方法

    公开(公告)号：US20100074893A1

    公开(公告)日：2010-03-25

    申请号：US12421836

    申请日：2009-04-10

    申请人： Annette Bistrup ,  Gundo Diedrich ,  Paul Levi Miller

    发明人： Annette Bistrup ,  Gundo Diedrich ,  Paul Levi Miller

    IPC分类号： A61K39/395 ,  C07K16/00 ,  C12N5/16 ,  C12P21/06 ,  G01N33/53 ,  G01N33/566

    CPC分类号： C07K16/18 ,  A61K2039/505 ,  C07K16/30 ,  C07K2317/34 ,  C07K2317/92 ,  G01N33/574 ,  G01N33/57415 ,  G01N33/57449

    摘要： The invention provides isolated anti-ECM-complex antibodies that bind to ECM-complexes. The invention also encompasses compositions comprising an anti-ECM-complex antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-ECM-complex antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-ECM-complex antibodies. The invention encompasses a method of producing the anti-ECM-complex antibodies. Other aspects of the invention are a method of detecting an ECM-complex expressing cancer, a method of inhibiting growth of an ECM-complex-expressing tumor, and a method of alleviating or treating an ECM-complex-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-ECM-complex antibody to the mammal.

    摘要翻译： 本发明提供了结合ECM-复合物的分离的抗ECM-复合物抗体。 本发明还包括包含抗ECM复合物抗体和载体的组合物。 这些组合物可以在制品或试剂盒中提供。 本发明的另一方面是编码抗ECM-复合物抗体的分离的核酸，以及包含分离的核酸的表达载体。 还提供了产生抗ECM复合物抗体的细胞。 本发明包括产生抗ECM复合物抗体的方法。 本发明的其它方面是检测ECM-复合物表达癌症的方法，抑制表达ECM-复合物的肿瘤生长的方法，以及减轻或治疗哺乳动物中表达ECM-复合物的癌症的方法，包括 向哺乳动物施用治疗有效量的抗ECM-复合物抗体。

    PRO115 antibody compositions and methods of use
    2.
    发明授权
    PRO115 antibody compositions and methods of use 有权
    PRO115抗体组合物和使用方法

    公开(公告)号：US08354508B2

    公开(公告)日：2013-01-15

    申请号：US12374292

    申请日：2007-07-20

    申请人： Gundo Diedrich ,  Paul Levi Miller ,  Jackie Papkoff ,  Astrid Strelow

    发明人： Gundo Diedrich ,  Paul Levi Miller ,  Jackie Papkoff ,  Astrid Strelow

    IPC分类号： C07K16/00 ,  C12P21/08 ,  C12N5/07 ,  C12N5/16

    CPC分类号： C07K16/30 ,  C07K16/40 ,  C07K2317/34 ,  C07K2317/76 ,  G01N33/57419 ,  G01N33/57423 ,  G01N33/57434 ,  G01N33/57438

    摘要： The invention provides isolated anti-Pro115 antibodies that bind to Pro115. The invention also encompasses compositions comprising an anti-Pro115 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro115 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro115 antibodies. The invention encompasses a method of producing the anti-Pro115 antibodies. Other aspects of the invention are a method of killing an Pro115-expressing cancer cell, comprising contacting the cancer cell with an anti-Pro115 antibody and a method of alleviating or treating an Pro115-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Pro115 antibody to the mammal.

    摘要翻译： 本发明提供了与Pro115结合的分离的抗Pro115抗体。 本发明还包括包含抗Pro115抗体和载体的组合物。 这些组合物可以在制品或试剂盒中提供。 本发明的另一方面是编码抗Pro115抗体的分离的核酸，以及包含分离的核酸的表达载体。 还提供产生抗Pro115抗体的细胞。 本发明包括产生抗Pro115抗体的方法。 本发明的其它方面是杀死表达Pro115的癌细胞的方法，包括使癌细胞与抗Pro115抗体接触，以及减轻或治疗哺乳动物中Pro115表达癌症的方法，包括给予治疗有效量 的抗Pro115抗体。

    PRO115 ANTIBODY COMPOSITIONS AND METHODS OF USE
    3.
    发明申请
    PRO115 ANTIBODY COMPOSITIONS AND METHODS OF USE 有权
    PRO115抗体组合物及其使用方法

    公开(公告)号：US20100150907A1

    公开(公告)日：2010-06-17

    申请号：US12374292

    申请日：2007-07-20

    申请人： Gundo Diedrich ,  Paul Levi Miller ,  Jackie Papkoff ,  Astrid Strelow

    发明人： Gundo Diedrich ,  Paul Levi Miller ,  Jackie Papkoff ,  Astrid Strelow

    IPC分类号： A61K39/395 ,  C07K16/18 ,  C12N5/16 ,  A61P35/00

    CPC分类号： C07K16/30 ,  C07K16/40 ,  C07K2317/34 ,  C07K2317/76 ,  G01N33/57419 ,  G01N33/57423 ,  G01N33/57434 ,  G01N33/57438

    摘要： The invention provides isolated anti-Pro115 antibodies that bind to Pro115. The invention also encompasses compositions comprising an anti-Pro115 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro115 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro115 antibodies. The invention encompasses a method of producing the anti-Pro115 antibodies. Other aspects of the invention are a method of killing an Pro115-expressing cancer cell, comprising contacting the cancer cell with an anti-Pro115 antibody and a method of alleviating or treating an Pro115-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Pro115 antibody to the mammal.

    摘要翻译： 本发明提供了与Pro115结合的分离的抗Pro115抗体。 本发明还包括包含抗Pro115抗体和载体的组合物。 这些组合物可以在制品或试剂盒中提供。 本发明的另一方面是编码抗Pro115抗体的分离的核酸，以及包含分离的核酸的表达载体。 还提供产生抗Pro115抗体的细胞。 本发明包括产生抗Pro115抗体的方法。 本发明的其它方面是杀死表达Pro115的癌细胞的方法，包括使癌细胞与抗Pro115抗体接触，以及减轻或治疗哺乳动物中Pro115表达癌症的方法，包括给予治疗有效量 的抗Pro115抗体。

    OVR110 antibody compositions and methods of use
    4.
    发明授权
    OVR110 antibody compositions and methods of use 有权
    OVR110抗体组合物和使用方法

    公开(公告)号：US08444971B2

    公开(公告)日：2013-05-21

    申请号：US12516397

    申请日：2007-11-27

    申请人： Jackie Papkoff ,  Gundo Diedrich ,  Shu-Hui Liu ,  Agnes Nowakowski

    发明人： Jackie Papkoff ,  Gundo Diedrich ,  Shu-Hui Liu ,  Agnes Nowakowski

    IPC分类号： A61K39/395

    CPC分类号： C07K16/2827 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/6817 ,  A61K47/6823 ,  A61K47/6849 ,  A61K47/6855 ,  A61K51/1027 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/30 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C12N9/96 ,  G01N33/57492 ,  A61K2300/00

    摘要： Isolated antibodies and antigen binding fragments thereof directed against Ovr110 which is expressed by head and neck, ovarian, endometrial, kidney, pancreatic, lung or breast cancer are provided. Also provided are cells and methods for their production as well as methods for their use in killing an Ovr110-expressing cancer cells and alleviating or treating an Ovr110-expressing cancer in a mammal. The anti-Ovr110 antibodies modulate Ovr110 function or internalize upon binding to Ovr110 expressed by mammalian cells in vitro and in vivo. Compositions comprising an anti-Ovr110 antibody and a carrier as well as articles of manufacture or kits thereof are also provided. In addition, isolated nucleic acids encoding an anti-Ovr110 antibody, expression vectors containing the isolated nucleic acids, and host cells containing the vectors are provided.

    摘要翻译： 提供了针对由头颈部，卵巢，子宫内膜，肾，胰腺，肺或乳腺癌表达的Ovr110的分离的抗体及其抗原结合片段。 还提供了用于其生产的细胞和方法及其用于杀死表达Ovr110的癌细胞并减轻或治疗哺乳动物中表达Ovr110的癌症的方法。 抗Ovr110抗体在体外和体内与哺乳动物细胞表达的Ovr110结合时调节Ovr110功能或内在化。 还提供了包含抗Ovr110抗体和载体及其制品或试剂盒的组合物。 此外，提供编码抗Ovr110抗体的分离的核酸，含有分离的核酸的表达载体和含有载体的宿主细胞。

    Methods of Determining Patient Response By Measurement of HER-2 Expression
    5.
    发明申请
    Methods of Determining Patient Response By Measurement of HER-2 Expression 审中-公开
    通过测量HER-2表达来确定患者反应的方法

    公开(公告)号：US20100233732A1

    公开(公告)日：2010-09-16

    申请号：US12688766

    申请日：2010-01-15

    申请人： Michael Bates ,  Jennifer W. Cook ,  Gundo Diedrich ,  Laurie Goodman ,  Ali Mukherjee ,  Gordon Parry ,  Jeff Sperinde ,  Stephen J. Williams

    发明人： Michael Bates ,  Jennifer W. Cook ,  Gundo Diedrich ,  Laurie Goodman ,  Ali Mukherjee ,  Gordon Parry ,  Jeff Sperinde ,  Stephen J. Williams

    IPC分类号： G01N33/574

    CPC分类号： G01N33/57415 ,  G01N33/57492 ,  G01N2333/71 ,  G01N2800/52

    摘要： Methods are provided for determining or otherwise assessing the response of a patient to treatment, in particular, to cancer treatment. The methods include the analysis of samples for the presence or the absence of HER2 markers alone or in conjunction with other biomarkers, such as HER3 markers. In certain examples, the probable time to progression can be determined by first determining HER2 positive patients and then further stratifying by using the presence or the absence of a second biomarker (e.g, HER3 markers). In addition, the data can be used to track a patient's response to a treatment regimen, assessing the expected success of treating a patient using a particular regiment, determining the effects of a treatment regiment or for categorizing a patient in order to create a homogenous group for a clinical trial.

    摘要翻译： 提供了用于确定或以其他方式评估患者对治疗，特别是癌症治疗的反应的方法。 这些方法包括单独或与其他生物标志物（如HER3标记物）结合存在或不存在HER2标记物的样品分析。 在某些实例中，可以通过首先确定HER2阳性患者，然后通过使用第二生物标志物（例如HER3标记）的存在或不存在进一步分层来确定进展的可能时间。 另外，数据可用于跟踪患者对治疗方案的反应，评估使用特定团治疗患者的预期成功率，确定治疗方案的效果或为了分类患者以创建均质组 进行临床试验。